

Ajinomoto inks manufacturing agreement for COVID-19 drug

07 May 2020 | News

Announces Manufacturing Partnership with CytoDyn for Drug Product Used in COVID-19 Clinical Trials



Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services with sites in Belgium, United States, Japan, and India, is pleased to announce it has entered into a manufacturing services agreement with CytoDyn Inc., a late stage biotechnology company, for the supply of the investigational new drug, leronlimab (PRO 140), which is currently being used in clinical trial protocols for Mild-to-Moderately Ill and Severely Ill COVID-19 patients.

Aji Bio-Pharma provides high quality drug product aseptic fill finish services for CytoDyn. Leronlimab, a novel CCR5 antagonist with the potential for multiple therapeutic indications, has been and is currently being administered to COVID-19 patients at New York City area hospitals as part of an emergency investigational new drug (EIND), granted by the U.S. Federal Drug Administration (FDA) as part of Phase 1, Phase 2 and Phase 2b/3 clinical trials. CytoDyn is currently enrolling patients in two placebo-controlled randomized clinical trials for Phase 2 and Phase 2b/3.